Published : 23 Sep 2020

---

Aagami is appointed by  a Clinical stage French Pharma developing a smoking cessation drug extracted from natural tobacco leaf , for supporting their investment and partnering needs.

 

The clients’ asset is quite revolutionary that it requires only 2 injections for complete smoking cessation. Phase II Clinical trials are in progress.

 

Earlier, Aagami, along with its Regulatory Expert Associate fulfilled the need of the same client with respect to Regulatory Pathway evaluation and report.

 

“Aagami’s performance and value addition has helped gain trust of our client to assign us another project. We are excited to bring success to our client, as soon as possible”, stated Godwyn Francis, Vice President, Aagami Inc.